Axiom International Investors LLC DE bought a new stake in ABIOMED, Inc. (NASDAQ:ABMD) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 34,404 shares of the medical equipment provider’s stock, valued at approximately $15,473,000. Axiom International Investors LLC DE owned approximately 0.08% of ABIOMED at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. MERIAN GLOBAL INVESTORS UK Ltd boosted its stake in ABIOMED by 1,030.0% during the 3rd quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 638,856 shares of the medical equipment provider’s stock valued at $287,325,000 after purchasing an additional 582,318 shares during the last quarter. Renaissance Technologies LLC boosted its stake in ABIOMED by 35.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,551,423 shares of the medical equipment provider’s stock valued at $634,610,000 after purchasing an additional 401,800 shares during the last quarter. BlackRock Inc. boosted its stake in ABIOMED by 10.3% during the 3rd quarter. BlackRock Inc. now owns 3,117,569 shares of the medical equipment provider’s stock valued at $1,402,127,000 after purchasing an additional 290,298 shares during the last quarter. Janus Henderson Group PLC boosted its stake in ABIOMED by 90.1% during the 3rd quarter. Janus Henderson Group PLC now owns 517,612 shares of the medical equipment provider’s stock valued at $232,797,000 after purchasing an additional 245,286 shares during the last quarter. Finally, FMR LLC boosted its stake in ABIOMED by 34.2% during the 2nd quarter. FMR LLC now owns 691,818 shares of the medical equipment provider’s stock valued at $282,988,000 after purchasing an additional 176,394 shares during the last quarter. 84.88% of the stock is owned by institutional investors and hedge funds.
In other news, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total value of $4,325,000.00. Following the transaction, the vice president now owns 48,954 shares in the company, valued at approximately $21,172,605. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.50% of the stock is owned by insiders.
A number of equities analysts have issued reports on ABMD shares. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. Morgan Stanley lifted their price target on ABIOMED from $370.00 to $396.00 and gave the company an “equal weight” rating in a research note on Thursday, October 11th. BTIG Research upgraded ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price target for the company in a research note on Friday, November 2nd. Finally, ValuEngine downgraded ABIOMED from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 18th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $402.78.
ABMD stock opened at $331.99 on Friday. The stock has a market cap of $14.14 billion, a price-to-earnings ratio of 135.51, a P/E/G ratio of 2.56 and a beta of 0.35. ABIOMED, Inc. has a 52-week low of $186.72 and a 52-week high of $459.75.
ABIOMED (NASDAQ:ABMD) last released its quarterly earnings results on Thursday, November 1st. The medical equipment provider reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.36. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The business had revenue of $181.78 million during the quarter, compared to the consensus estimate of $175.41 million. During the same quarter in the previous year, the business earned $0.54 EPS. The company’s quarterly revenue was up 36.9% on a year-over-year basis. Equities research analysts expect that ABIOMED, Inc. will post 3.57 earnings per share for the current fiscal year.
WARNING: “Axiom International Investors LLC DE Buys New Stake in ABIOMED, Inc. (ABMD)” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/11/30/axiom-international-investors-llc-de-buys-new-stake-in-abiomed-inc-abmd.html.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Featured Story: Trading Strategy Methods for Individual Investors
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.